Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
AstraZeneca’s potential blockbuster pill halves high cholesterol
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
Clinical Trials Arena on MSN4d
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
AstraZeneca says AZD0780 demonstrates significant LDL-C reduction in trial
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
STAT1d
NIH hit with chaos, cuts, and contractor purge
The NIH is scrambling to slash $2.6 billion in contracts — about 35% of them — by April 8, per the instruction of the U.S.
Fierce Biotech5d
AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
Stock Movers: Astrazeneca, Tesco, Travis Perkins
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
NBC Washington4d
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...